This site is intended only for healthcare professionals resident in Egypt
Nimenrix® is approved as a single dose from 12 months of age.2
Nimenrix® is a licensed meningococcal conjugate vaccine for serogroups A, C, W-135, and Y that can be administered at age 6 weeks with no upper age limit and with broad age indication2
Adapted from Nimenrix (Meningococcal group A, C, W-135 and Y conjugate vaccine). [Local product document]. May 2022.
Preparation & Storage
Nimenrix® can be administered in a few steps.2
Route of administration2
Immunisation should carried out by intramuscular injection only. In infants, the recommended injection site is the anterolateral aspect of the thigh. In individuals aged ≥1 year, the recommended injection site is the anterolateral aspect of the thigh or the deltoid muscle.
Nimenrix® allows concomitant administration with the standard vaccine calendar.2
*In some situations, consideration may be given to administering an additional primary dose or a booster dose of Nimenrix®
†Nimenrix® should be used in accordance with official recommendations2
A second dose of Nimenrix® may be considered appropriate for some individuals.
Approval Code: BF0098OA686/052023
Invalidation date: 10/05/2025
Adverse events should be reported. Adverse events can be reported to [email protected]
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries.
Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.
These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
If you select ‘No’, you will be redirected to Pfizer.com, the global Pfizer website.
I confirm that I am a healthcare professional resident in Egypt.